Pharmacokinetic comparison between fixed-dose combination of fimasartan/amlodipine 60/10 mg and the corresponding loose combination through partial replicated crossover study in healthy subjects

Eunsol Yang, Soyoung Lee, Heechan Lee, Inyoung Hwang, In-Jin Jang, Kyung-Sang Yu and SeungHwan Lee*

Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul 03080, Republic of Korea
*Correspondence: SH Lee; Tel: +2-2072-2343, Fax: +2-742-9252, E-mail: leejh413@snu.ac.kr

Introduction
Hypertension is a major risk factor for cardiovascular diseases, so blood pressure (BP) control is important in preventing relevant complications.[1] According to the hypertension management guideline of the Korean Society of Hypertension, if the systolic blood pressure (SBP)/diastolic blood pressure (DBP) exceeds 160/100 mmHg, or is 20/10 mmHg higher than the tar-
get BP, combination therapy with two antihypertensive agents of different classes is recommended.[2] Especially, it is well known that the concomitant use of a calcium channel blocker (CCB) with an angiotensin II receptor blocker (ARB) is more effective than doubling the dose of one single drug.[3-6]

Fimasartan, an ARB, is rapidly absorbed, reaching its maximum plasma concentration (C_{\text{max}}) in 0.5–3.0 hours, and has a terminal elimination half-life of 9.0–16.0 hours. More than 90% of fimasartan in the plasma presents as the parent drug, and its relatively very small portion undergoes metabolism, mainly by CYP3A4.[7] Additionally, fimasartan is known as a highly variable drug (HVD), in that its intra-subject variability for C_{\text{max}} is larger than 30%.[8-10] Amlodipine, a CCB, reaches at C_{\text{max}} within 6.0–8.0 hours and has a terminal elimination half-life of 40–60 hours,[11] and it is extensively metabolized by CYP3A4.

In a previous drug-drug interaction study, there was no clinically relevant pharmacokinetic (PK) interaction between fimasartan and amlodipine.[7]

Fixed-dose combination (FDC) is known to improve patients’ compliance and reduce medical costs, and it may be more effective in controlling BP in some patients.[13-16] Referring to these points, an FDC tablet of fimasartan/amlodipine 60/10 mg was developed by Boryung Pharmaceutical Co., Ltd. (Seoul, Republic of Korea).

According to the bioequivalence study guidelines of the regulatory agencies, including the Korea Ministry of Food and Drug Safety (MFDS), a replicated crossover design can be used for bioequivalence studies of an HVD, and a widened bioequivalence range can be accepted.[17-19] Since fimasartan is an HVD, a full or partial replicated crossover design can be selected for the bioequivalence study between FDC of fimasartan/amlodipine 60/10 mg and the corresponding loose combination.

The aim of this study was to compare the PK characteristics and evaluate the bioequivalence between FDC of fimasartan/amlodipine 60/10 mg and the corresponding loose combination in healthy male subjects.

**Methods**

**Subjects and study design**

The study protocol was approved by the institutional review board of Seoul National University Hospital (Seoul, Republic of Korea) and MFDS (NCT02920047). All the procedures were performed in compliance with the Korean Good Clinical Practice guidelines and tenets of the Declaration of Helsinki. All the subjects provided written informed consent prior to any procedures related to the study.

This study included healthy male subjects between 19 and 50 years of age, weighing ≥ 55 kg and with a body mass index ranging from 18.0 to 27.0 kg/m². All subjects had no clinically significant abnormalities based on their medical histories, vital signs, physical examination, clinical laboratory tests, and 12-lead electrocardiogram (ECG). Subjects with any hypersensitivity to drugs such as fimasartan and amlodipine were excluded from the study. Additionally, subjects having SBP ≤ 100 mmHg or ≥ 140 mmHg, or DBP ≤ 65 mmHg or ≥ 90 mmHg were excluded from the study at the screening.

This study was designed as a randomized, open-label, two-treatment, three-period, three-sequence, partial replicated crossover study with 14-days washout between periods. The enrolled subjects were randomly assigned to one of the three sequences, and received a single oral dose of an FDC tablet of fimasartan/amlodipine 60/10 mg (Boryung Pharmaceutical Co., Ltd., Seoul, Republic of Korea) as the test drug, or a loose combination of fimasartan 60 mg (Kanarb® tablet 60 mg, Boryung Pharmaceutical Co., Ltd.) and amlodipine 10 mg (Norvasc® tablet 10 mg, Pfizer Inc., Seoul, Republic of Korea) as the reference drug in each period. Each sequence consisted of a single oral administration of the test drug in one period and the reference drug in the other two periods (Sequence A: Reference → Reference → Test; Sequence B: Reference → Test → Reference; Sequence C: Test → Reference → Reference).

Blood samples for PK analysis of fimasartan were collected at 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 12, 24, and 48 h post-dose. For amlodipine, blood samples were collected at 0 (pre-dose), 1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, 72, 96, and 144 h post-dose. Approximately 5 or 8 mL of the blood sample was collected in a heparinized tube for each blood sampling point and subsequently centrifuged at 3,000 rpm for 10 minutes at 4°C. The supernatants were then transferred to three Eppendorf tubes and stored at −70°C until analysis.

**Determination of plasma fimasartan and amlodipine concentrations**

Plasma concentrations of fimasartan and amlodipine were analyzed at Kyung Hee Drug Analysis Center of Kyung Hee University (Seoul, Republic of Korea).

Plasma concentrations of fimasartan were determined by a validated high-performance liquid chromatography (HPLC, Agilent 1200 series, Agilent Technologies, USA) coupled with tandem mass spectrometry method (MS/MS, The Applied Biosystems MDS SCIEX API 4000 triple quadrupole mass spectrometer, Applied Biosystems, Canada). In the HPLC system, a Luna C18 column (50 × 2.0 mm, 3.0 μm, Phenomenex, USA) was used for the chromatographic separation of fimasartan and BR-A-563 (Internal standard; IS) under gradient conditions. The MS/MS system was operated in the ionization mode using positive ion electrospray and the multiple reaction monitoring (MRM) mode. The MRM mode was monitored based on an m/z transition of 502.4 → 207.1 for fimasartan and 526.5 → 207.2 for BR-A-563 (IS).

Plasma concentrations of amlodipine were determined by a validated HPLC (Agilent 1100 series, Agilent Technologies, USA) coupled with MS/MS method (The Applied Biosystems MDS SCIEX API 2000 triple quadrupole mass spectrometer,
The mean plasma concentration-time profiles and PK characteristics of fimasartan were similar between the FDC and loose combination (Fig. 1A, Table 1). For fimasartan, the majority of the subjects exhibited double-peak plasma concentration-time profiles. Unlike the individual AUC_{last} values of fimasartan, the individual C_{max} values of fimasartan were highly variable between two treatments (Fig. 2A, 2B). The GMRs (90% CIs) of the FDC to the loose combination for C_{max} and AUC_{last} of fimasartan were 1.0440 (0.9202–1.1844) and 1.0412 (0.9775–1.1090), respectively. Since the intra-subject CV% for the C_{max} of fimasartan was 48.51%, the expanded bioequivalence range for the C_{max} of fimasartan was 0.7051–1.4182.[17,19] The GMR and its 90% CI for C_{max} of fimasartan fell not only within the expended bioequivalence range but also within the conventional bioequivalence criteria of 0.80–1.25. The corresponding values for the AUC_{last} of fimasartan were also included in the conventional bioequivalence criteria (Table 2).

The mean plasma concentration-time profiles and PK parameters of amlodipine were comparable between the FDC and loose combination (Fig. 1B, Table 1). The individual values of
Cmax and AUClast of amlodipine showed no significant variations between the two treatments (Fig. 2C, 2D). The GMRs (90% CIs) of the FDC to the loose combination for Cmax and AUClast of amlodipine were 1.0430 (1.0156–1.0711) and 1.0339 (1.0055–1.0631), respectively. All the GMRs and their 90% CIs for Cmax and AUClast of amlodipine were within the conventional bioequivalence criteria of 0.80–1.25 (Table 2).

**Effect on blood pressure**

The reductions in SBP and DBP were similar between the FDC and loose combination (Fig. 3); In the FDC and loose combination groups, the lowest mean ± standard deviation values of SBP were 101.7 ± 8.9 mmHg and 101.4 ± 8.8 mmHg, respectively, and the corresponding values of DBP were 56.8 ± 5.9 mmHg and 57.1 ± 6.0 mmHg, respectively.

**Safety and tolerability assessments**

No clinically significant changes were observed in clinical laboratory tests, 12-lead ECG, physical examination, and vital signs. During the study, a total of 44 treatment-emergent AEs (TEAEs) were reported in 24 subjects. Among them, 15 TEAEs occurred in 11 subjects who received the FDC, and 29 TEAEs...
Pharmacokinetics of fixed-dose combination of fimasartan/amlodipine in replicated crossover study

There was no significant difference in the TEAEs between the two treatments ($p$-value = 0.8338).

**Discussion**

This study compared the PK properties and evaluated the bioequivalence between FDC of fimasartan/amlodipine 60/10 mg and the corresponding loose combination. The FDC and loose combination showed similar PK characteristics in healthy male subjects. The GMR and its 90% CI for $C_{max}$ of fimasartan were included in the scaled bioequivalence criteria, which was 0.7051–1.4182. Also, the GMRs and their 90% CIs for the other PK parameters are included in Table 2. The geometric mean ratios and 90% CIs for the other PK parameters are also included in Table 2.

**Figure 2.** Individual comparison of (A) $C_{max}$ and (B) AUC$_{last}$ of fimasartan, and (C) $C_{max}$ and (D) AUC$_{last}$ of amlodipine following a single administration of fixed-dose combination (FDC) of fimasartan/amlodipine 60/10 mg or the corresponding loose combination.

**Table 2.** Comparison of pharmacokinetic parameters of fimasartan and amlodipine between fixed dose-combination (FDC) of fimasartan/amlodipine 60/10 mg and the corresponding loose combination

| Drug     | PK Parameter | Geometric mean | Geometric Mean Ratio$^b$ (90% CI) | Scaled BE criteria |
|----------|--------------|----------------|-----------------------------------|--------------------|
|          | FDC          | Loose combination$^a$ |                                  |                    |
| Fimasartan | $C_{max}$ (μg/L) | 83.66          | 80.14                             | 1.0440 (0.9202–1.1844) | 0.7051–1.4182 |
|          | AUC$_{last}$ (h*μg/L) | 437.73         | 420.40                            | 1.0412 (0.9775–1.1090) | - |
| Amlodipine | $C_{max}$ (μg/L) | 5.84           | 5.59                              | 1.0430 (1.0156–1.0711) | - |
|          | AUC$_{last}$ (h*μg/L) | 255.85         | 247.47                            | 1.0339 (1.0055–1.0631) | - |

PK, pharmacokinetic; CI, confidence interval; BE, bioequivalence; $C_{max}$, maximum plasma concentration; AUC$_{last}$, area under the concentration-time curve from 0 to last measurable time point.

$^a$Data from 1st and 2nd dosing of loose combination of fimasartan 60 mg tablet and amlodipine 10 mg tablet in 56 subjects were used.

$^b$Geometric mean ratio is the ratio of the FDC to the loose combination.

occurred in 18 subjects who received the loose combination. There was no significant difference in the TEAEs between the two treatments ($p$-value = 0.8338).
PK variables of drugs were within the conventional bioequivalence criteria of 0.80–1.25. These results indicated that the FDC was bioequivalent to the loose combination when administered to healthy male subjects.

Conventional 2 × 2 crossover bioequivalence studies with HVDs have the disadvantage of requiring large sample sizes for attaining sufficient statistical power. According to the guidelines of the regulatory agencies, a replicated crossover design can be used for bioequivalence studies with HVDs,[17-19] and it is helpful for reducing the number of subjects needed to demonstrate bioequivalence by up to about 50%.[20] Based on the highest observed intra-subject CV% for the Cmax of fimasartan (62%), approximately 114 subjects would be required for detecting a 20% difference between the two treatments with 80% statistical power at a 5% level of significance under the conventional 2 × 2 crossover design, while this study could reduce the number of subjects by up to 60 subjects through the partial replicated crossover design by widening the bioequivalence range. Using the intra-subject CV% for the Cmax of fimasartan calculated in this study (48.51%), about 57 subjects are enough to achieve the conventional bioequivalence criteria with 80% statistical power at a 5% level of significance under partial replicated design. Therefore, a sample size of 60 subjects chosen in this study was sufficient to assess the conventional bioequivalence as well as the scaled bioequivalence through partial replicated design between the FDC of fimasartan/amlodipine 60/10 mg and the corresponding loose combination.

Although the subjects had normal BP, BP was monitored as a safety assessment. After a single administration of the FDC or the loose combination, the maximal decreases in SBP/DBP were 11.41/12.12 mmHg and 12.56/12.21 mmHg, respectively. Although BP evaluation was not the primary aim of this study, these results suggest that FDC of fimasartan/amlodipine 60/10 mg will show similar BP-lowering effects compared to the corresponding loose combination.

In conclusion, FDC of fimasartan/amlodipine 60/10 mg showed similar PK profiles with the corresponding loose combination. The GMRs and their 90% CIs for Cmax and AUClast of fimasartan and amlodipine fell not only within the scaled bioequivalence criteria but also within the conventional bioequivalence criteria, indicating the bioequivalence between the FDC and loose combination.

Acknowledgments
This study was sponsored by Boryung Pharmaceutical Co., Ltd., Seoul, Republic of Korea.

Conflict of interest
- Authors: Heechan Lee is currently employed by Hanall BioPharma Co., Ltd., Seoul, Republic of Korea. His contribution to the manuscript was based on his prior employment, and the current manuscript does not reflect any position of Hanall BioPharma Co., Ltd.. All the other authors have no competing interests to declare.
- Reviewers: Nothing to declare
- Editors: Nothing to declare

References
1. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996;275:1571-1576.
2. Lee HY, Shin J, Kim GH, Park S, Ihm SH, Kim HC, et al. 2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension. Clin Hypertens 2019;25:20. doi: 10.1186/s40885-019-0124-x.
3. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300. doi: 10.1016/j. amjmed.2008.09.038.
4. Chrysant SG. The role of Angiotensin receptor blocker and calcium channel blocker combination therapy in treating hypertension: focus on recent studies. Am J Cardiovasc Drugs 2010;10:315-320. doi: 10.2165/1138850-
Pharmacokinetics of fixed-dose combination of fimasartan/amlodipine in replicated crossover study

00000000-00000.

5. da Silva PM. Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan. Clin Drug Investig 2010;30:625-641. doi: 10.2165/11538440-000000000-00000.

6. Ishimitsu T, Ohno E, Nakano N, Furukata S, Akashiba A, Minami J, et al. Combination of angiotensin II receptor antagonist with calcium channel blocker or diuretic as antihypertensive therapy for patients with chronic kidney disease. Clin Exp Hypertens 2011;33:366-372. doi: 10.3109/10641963.2010.503299.

7. Yi S, Kim TE, Yoon SH, Cho JY, Shin SG, Jang JJ, et al. Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers. J Cardiovasc Pharmacol 2011;57:682-689. doi: 10.1097/FJC.0b013e31821795d0.

8. Kang WY, Seong SJ, Ohk B, Gwon MR, Kim BK, Cho S, et al. Pharmacokinetic and bioequivalence study comparing a fimasartan/rosuvastatin fixed-dose combination with the concomitant administration of fimasartan and rosuvastatin in healthy subjects. Drug Des Devel Ther 2018;12:3607-3615. doi: 10.2147/dddt.S161917.

9. Ghim JL, Paik SH, Hasanuzzaman M, Chi YH, Choi HK, Kim DH, et al. Absolute bioavailability and pharmacokinetics of the angiotensin II receptor antagonist fimasartan in healthy subjects. J Clin Pharmacol 2016;56:576-580. doi: 10.1002/jcpp.618.

10. Chi YH, Lee H, Paik SH, Lee JH, Yoo BW, Kim JH, et al. Safety, Pharmacokinetics, and Pharmacodynamics of Fimasartan Following Single and Repeated Oral Administration in the Fasted and Fed States in Healthy Subjects. Am J Cardiovac Drugs 2011;11:335-348. doi: 10.2165/11593840-000000000-00000.

11. Abernethy DR. Pharmacokinetics and pharmacodynamics of amlodipine. Cardiology 1992;80 Suppl 1:31-36. doi: 10.1159/000175050.

12. Son M, Guk J, Kim Y, Woo Chae D, Heo YA, Soh D, et al. Pharmacokinetic Interaction Between Rosuvastatin, Telmisartan, and Amlodipine in Healthy Male Korean Subjects: A Randomized, Open-label, Multiple-dose, 2-period Crossover Study. Clin Ther 2016;38:1845-1857. doi: 10.1016/j.clinthera.2016.06.011.

13. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-719. doi: 10.1016/j.amjmed.2006.08.033.

14. Stankus V, Hemmelgamb B, Campbell NR, Chen G, McAlister FA, Tsuyuki RT. Reducing costs and improving hypertension management. Can J Clin Pharmac 2009;16:e151-e155.

15. Sherrill B, Halpern M, Khan S, Zhang J, Panjabi S. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich) 2011;13: 898-909. doi: 10.1111/j.1751-7176.2011.00550.x.

16. Sakima A, Ohshiro K, Nakada M, Yamazato M, Kohagura K, Nakamoto M, et al. Switching therapy from variable-dose multiple pill to fixed-dose single-pill combinations of angiotensin II receptor blockers and thiazides for hypertension. Clin Exp Hypertens 2011;33:309-315. doi: 10.3109/10641963.2010.549260.

17. EMA Guideline on the Investigation of Bioequivalence. London: European Medicines Agency (EMA). 2010

18. FDA Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA. Guidance for Industry. 2013

19. MFDS Guidelines for Bioequivalence Studies for Drugs. MFDS (Ministry of Food and Drug Safety), 2014

20. Van Peer A. Variability and impact on design of bioequivalence studies. Basic Clin Pharmacol Toxicol 2010;106:146-153. doi: 10.1111/j.1742-7843.2009.00485.x.